ONCONETIX

What this means for you

Not registered yet, but its 13 Nov 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

98267927

Mark type

Stylized text

Filed

13 Nov 2023

Published for opposition

06 Aug 2024

Attorney of record

Danielle Cohen, Esq.

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of cancer featuring small molecules, biopharmaceuticals, Antibody-Drug-Conjugates (ADCs), Oncolytic viruses, virus-like particles-based therapeutics, and nano-encapsulated drug like synthetic therapeutics; Pharmaceutical preparations for the treatment of cancer for use in cellular therapies, gene therapies, N - 1 personalized drug therapies, and CAR T-cell therapy; Pharmaceutical preparations for the treatment of cancer derived from CRISPR-Cas9 and CAR T-Cell; Vaccine preparations; Antibodies for medical purposes, namely, monoclonal antibodies and bi-specific antibodies; Medical diagnostic reagents and diagnostic preparations for use in-vitro, in-vivo, cell-based assays, cell culture processes, laboratory-developed tests (LDTs), cell-based imagining, genomics, gene-based expression assays, proteomics, protein-based expression assays, immunohistochemistry (IHC), drug sensitivity and treatment diagnostics
• Class 009 — Scientific and electric apparatus: Downloadable medical computer software platforms containing diagnostic algorithms and decision-making computation to support screening, diagnosing, monitoring and treatment modalities of diseases; downloadable medical computer software platforms for aiding in decision-making in clinical and after-regulatory approval of therapeutics and diagnostics; downloadable medical computer software platforms for managing and maintaining pre-clinical trials, clinical trials and assessments of patient's tumors in their staging and treatment
• Class 010 — Medical apparatus: Medical apparatus for personalized medical therapeutics, namely, infusion and injection devices for administering therapeutic drugs of various types, namely, small molecules, biopharmaceuticals, cellular therapies, gene therapies, vaccines, CRISPR-Cas9 derived, CAR T-Cell derived, N - 1 personalized drug therapies, Antibody-Drug-Conjugates (ADCs), Oncolytic viruses, monoclonal antibodies, bi-specific antibodies, virus-like particles-based therapeutics, and nano-encapsulated drug like synthetic therapeutics, into the human body utilizing both in-vivo and in-vitro, gene or cellular therapy methods
• Class 042 — Scientific and technological services: Medical research services in personalized medicine, patient treatment, therapeutics and diagnostics
• Class 044 — Medical, beauty and agricultural services: Biobanking services, namely, human and animal organ and tissue bank services; Medical digital pathology services for diagnostic or treatment purposes of human and animal tumors; Medical imaging services for cellular systems for the characterization of human and animal tumors

Owner

• ONCONETIX, INC., CINCINNATI, OH, US
• ONCONETIX, INC., CINCINNATI, OH, US
• BLUE WATER BIOTECH, INC., CINCINNATI, OH, US

Prosecution history

• 25 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 25 Mar 2026 — SOU EXTENSION 3 GRANTED
• 25 Mar 2026 — SOU EXTENSION 3 FILED
• 25 Mar 2026 — SOU TEAS EXTENSION RECEIVED
• 25 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 25 Sept 2025 — SOU EXTENSION 2 GRANTED
• 25 Sept 2025 — SOU EXTENSION 2 FILED
• 25 Sept 2025 — SOU TEAS EXTENSION RECEIVED
• 01 Apr 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 31 Mar 2025 — SOU EXTENSION 1 GRANTED
• 31 Mar 2025 — SOU EXTENSION 1 FILED
• 31 Mar 2025 — SOU TEAS EXTENSION RECEIVED
• 01 Oct 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
• 06 Aug 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 06 Aug 2024 — PUBLISHED FOR OPPOSITION